Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 10/20 | 0.65 |
| ▸ | ECE1 | P42892 | 1/20 | 0.65 |
| ▸ | MUS81 | Q96NY9 | 1/20 | 0.65 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.63 |
| ▸ | PTH1R | Q03431 | 2/20 | 0.61 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.59 |
| ▸ | NPBWR1 | P48145 | 3/20 | 0.58 |
| ▸ | SLC2A1 | P11166 | 2/20 | 0.58 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31087271 | 0.96 | RXFP1 (0.68) | GLP1RECE1MUS81RXFP1PTH1R | |
| SCHEMBL30271994 | 0.96 | RXFP1 (0.68) | GLP1RECE1MUS81RXFP1PTH1R | |
| SCHEMBL30076208 | 0.96 | GLP1R (0.63) | GLP1RECE1MUS81RXFP1PTH1R | |
| SCHEMBL29462132 | 0.95 | RXFP1 (0.70) | GLP1RECE1MUS81RXFP1PTH1R | |
| SCHEMBL30183270 | 0.95 | RXFP1 (0.70) | GLP1RECE1MUS81RXFP1PTH1R | |
| SCHEMBL30049211 | 0.95 | RXFP1 (0.66) | GLP1RECE1MUS81RXFP1PTH1R | |
| SCHEMBL31759108 | 0.94 | RXFP1 (0.67) | GLP1RECE1MUS81RXFP1PTH1R | |
| SCHEMBL31453813 | 0.94 | RXFP1 (0.70) | GLP1RECE1MUS81RXFP1PTH1R | |
| SCHEMBL30635326 | 0.93 | RXFP1 (0.70) | GLP1RECE1MUS81RXFP1PTH1R | |
| SCHEMBL29848900 | 0.93 | RXFP1 (0.67) | GLP1RECE1MUS81RXFP1PTH1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3433267-B1 | METHOD FOR PREPARING GLUCAGON-LIKE PEPTIDES | BACHEM HOLDING AG (CH) | 2022-08-24 | — | — | EP | claimed |
| US-20250188115-A1 | PROCESS FOR PREPARING A GLUCAGON-LIKE PEPTIDE | CHEMICAL & BIOPHARMACEUTICAL LABORATORIES OF PATRAS S.A. (GR) | 2025-06-12 | — | — | US | disclosed |
| WO-2025078040-A1 | LYSINE SALT AND METHOD OF MANUFACTURING A LYSINE DERIVATIVE | BACHEM HOLDING AG (CH) | 2025-04-17 | — | — | WO | disclosed |
| CN-116120427-B | Semex lattice Synthesis method of lupeptide | 浙江九洲药业股份有限公司 | 2024-12-10 | — | — | CN | disclosed |
| WO-2024159569-A1 | METHOD FOR SYNTHESIZING SEMAGLUTIDE | 浙江九洲药业股份有限公司 | 2024-08-08 | — | — | WO | disclosed |
| CN-117624332-A | Preparation method of cable Ma Lutai | 合肥科生景肽生物科技有限公司 | 2024-03-01 | — | — | CN | disclosed |
| CN-112912390-B | GLP-1 analogues and methods of preparation | 北京费森尤斯卡比医药有限公司 | 2023-12-15 | — | — | CN | disclosed |
| CN-116813693-B | Label compound for polypeptide synthesis and application of label compound in polypeptide synthesis | 苏州金顶生物有限公司 | 2023-12-01 | — | — | CN | disclosed |
| CN-117084971-A | Liraglutide nasal administration in-situ temperature-sensitive gel preparation, and preparation method and application thereof | 成都大学 | 2023-11-21 | — | — | CN | disclosed |
| CN-116836258-A | Solid phase synthesis method of liraglutide | 辽宁药联制药有限公司 | 2023-10-03 | — | — | CN | disclosed |
| EP-4217503-A1 | A PROCESS FOR THE PREPARATION OF SEMAGLUTIDE AND SEMAPEPTIDE | Dr. Reddy's Laboratories Limited (IN) | 2023-08-02 | — | — | EP | disclosed |
| CN-116120427-A | Synthesis method of semaglutin | 浙江九洲药业股份有限公司 | 2023-05-16 | — | — | CN | disclosed |
| WO-2023279323-A1 | METHOD FOR SYNTHESIZING GLP-1 ANALOG | 深圳翰宇药业股份有限公司 | 2023-01-12 | — | — | WO | disclosed |
| WO-2022266927-A1 | LIRAGLUTIDE VARIANT, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | 深圳翰宇药业股份有限公司 | 2022-12-29 | — | — | WO | disclosed |
| CN-113024658-B | Method for purifying liraglutide | 翰宇药业（武汉）有限公司 | 2022-10-21 | — | — | CN | disclosed |
| EP-3433267-B1 | METHOD FOR PREPARING GLUCAGON-LIKE PEPTIDES | BACHEM HOLDING AG (CH) | 2022-08-24 | — | — | EP | disclosed |
| US-11396533-B2 | Process for the manufacture of GLP-1 analogues | Fresenius Kabi Ipsum S.R.L. (IT) | 2022-07-26 | — | — | US | disclosed |
| US-20220195004-A1 | METHOD FOR PREPARING TARGET POLYPEPTIDE BY MEANS OF RECOMBINATION AND SERIES CONNECTION OF FUSED PROTEINS | PEG-BIO BIOPHARM CO., LTD. (CHONGQING) (CN) | 2022-06-23 | — | — | US | disclosed |
| WO-2022064517-A1 | A PROCESS FOR THE PREPARATION OF SEMAGLUTIDE AND SEMAPEPTIDE | DR. REDDY'S LABORATORIES LIMITED (IN) | 2022-03-31 | — | — | WO | disclosed |
| US-20220041680-A1 | PROCESS FOR THE MANUFACTURE OF GLP-1 ANALOGUES | Fresenius Kabi Ipsum S.R.L. (IT) | 2022-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220041680-A1 | PROCESS FOR THE MANUFACTURE OF GLP-1 ANALOGUES | GLP1R, IAPP, VIP | GLP1R 1/4885ECE1 1243/4885MUS81 4016/4885 |
| US-11396533-B2 | Process for the manufacture of GLP-1 analogues | GLP1R, IAPP, VIP | GLP1R 1/4885ECE1 1243/4885MUS81 4016/4885 |
| US-20250188115-A1 | PROCESS FOR PREPARING A GLUCAGON-LIKE PEPTIDE | GLP1R, IAPP, GCG | GLP1R 1/4885ECE1 1694/4885MUS81 3775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.